The Mahamaya Lifesciences IPO will open on November 11, 2025, and close on November 13, 2025. The Mahamaya Lifesciences IPO is a book-built issue. The company will raise approximately ₹70.44 crore through the IPO, consisting of fresh shares worth ₹64.28 crore and 540,800 equity shares with a face value of ₹10.
The price band for the Mahamaya Lifesciences IPO is ₹108 to ₹114 per share. The retail portion is 35%, QIBs 50%, and HNIs 15%. The Mahamaya Lifesciences IPO will be listed on the BSE on November 18, 2025. The allotment for the Mahamaya Lifesciences IPO will take place on November 14, 2025.
The company reported revenue of ₹267.17 crore in 2025, compared to ₹162.83 crore in 2024. The company reported a profit of ₹12.94 crore in 2025, compared to ₹5.22 crore in 2024. Based on the financials, IPO investors should invest in the IPO GMP for the long term.
Mahamaya Lifesciences IPO Details
| IPO Open Date | November 11, 2025 |
| IPO Close Date | November 13, 2025 |
| Face Value | ₹10 Per Equity Share |
| IPO Price Band | ₹108 to ₹114 Per Share |
| Issue Size | Approx ₹70.44 Crores |
| Fresh Issue | Approx ₹64.28 Crores |
| Offer for Sale: | Approx 5,40,000 Equity Shares |
| Issue Type | Book Built Issue |
| IPO Listing | BSE SME |
| DRHP Draft Prospectus |  |
| RHP Draft Prospectus | |
Mahamaya Lifesciences IPO Market Lot
The Mahamaya Lifesciences IPO minimum market lot is 2,400 shares with ₹2,73,600 application amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 2,400 | ₹2,73,600 |
| Retail Maximum | 2 | 2,400 | ₹2,73,600 |
| S-HNI Minimum | 3 | 3,600 | ₹4,10,400 |
| S-HNI Maximum | 7 | 8,400 | ₹9,57,600 |
| B-HNI Minimum | 8 | 9,600 | ₹10,94,400 |
IPO Reservation
| Investor Category | Share Offered | -% Shares |
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 50% |
| NII Shares Offered | – Shares | 15% |
| Retail Shares Offered | – Shares | 35% |
Mahamaya Lifesciences IPO Anchor Investors
| Anchor Bidding Date | November 10, 2025 |
| Anchor Investors List | . |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| lock-in period end date 50% shares (30 Days) | December 14, 2025 |
| lock-in period end date 50% shares (90 Days) | February 12, 2026 |
Mahamaya Lifesciences IPO Dates
The Mahamaya Lifesciences IPO date is November 11 and the close date is November 13. The Mahamaya Lifesciences IPO allotment will be finalized on November 14 and the IPO listing on November 18.
| IPO Open Date: | November 11, 2025 |
| IPO Close Date: | November 13, 2025 |
| Basis of Allotment: | November 14, 2025 |
| Refunds: | November 17, 2025 |
| Credit to Demat Account: | November 17, 2025 |
| IPO Listing Date: | November 18, 2025 |
| IPO Bidding Cut-off Time: | November 13, 2025 – 5 PM |
Promoters and Holding Pattern
The promoters of the company are Mr. Krishnamurthy Ganesan, Mr. Prashant Krishnamurthy, and Mrs. Lalitha Krishnamurthy.
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 1,77,66,200 | 77.27% |
| Promoter Holding Post Issue | 2,34,05,000 | 56.35% |
Objects of the Issue & Utilisation of proceeds
| Purpose | Crores |
| Purchase of Equipment for existing Formulation plant. | ₹3.75 |
| Funding capital expenditure towards setting up of a new Technical manufacturing plant. | ₹29.42 |
| Construction of Warehouse Building and Purchase of Machinery. | ₹2.53 |
| Funding working capital requirement of the Company. | ₹18.00 |
| General Corporate purposes. | ₹- |
About Mahamaya Lifesciences IPO
Established in 2002, Mahamaya Lifesciences Limited is one of the leading companies focused on the manufacture and supply of bulk pesticide formulations. In collaboration with the Central Insecticides Board and Registration Committee (CIBRC), the company began its business by importing and registering key pesticide molecules not produced in India. Following successful registration, the company decided to sell these molecules as technical products to Indian agrochemical companies as well as multinational corporations (MNCs).
Since its inception in 2002, the company has made significant progress, establishing its own manufacturing plant in Dahej, Gujarat, in December 2021. Its products have reached various states in India, such as Punjab, Haryana, Rajasthan, Uttar Pradesh, Gujarat, Maharashtra, Andhra Pradesh, and Telangana, while internationally, it exports its products to Turkey, Egypt, and the United Arab Emirates.
Mahamaya Lifesciences IPO Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2022 | ₹90.16 | ₹86.43 | ₹2.72 | ₹55.71 |
| 2023 | ₹137.40 | ₹132.30 | ₹3.75 | ₹77.88 |
| 2024 | ₹162.83 | ₹155.71 | ₹5.22 | ₹112.07 |
| 2025 | ₹267.17 | ₹249.81 | ₹12.94 | ₹188.35 |
| June 2025 | ₹84.04 | ₹78.35 | ₹4.10 | ₹218.87 |
Mahamaya Lifesciences IPO Valuation – FY2025
Check Mahamaya Lifesciences IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 34.94% |
| ROCE: | 23.15% |
| EBITDA Margin: | 9.22% |
| PAT Margin: | 4.84% |
| Debt to equity ratio: | 1.08 |
| Earning Per Share (EPS): | ₹7.60 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 26.19% |
| Net Asset Value (NAV): | ₹27.82 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Nova Agritech Limited | 3.05 | 16.93 | 12.47% | 23.76 | 296.60 Cr. |
| Bhagiradha Chemicals & Industries Limited | 1.14 | 247.63 | 2.03% | 52.61 | 449.75 Cr. |
Mahamaya Lifesciences Limited (MLL) specializes in the manufacture of pesticide formulations and supplies bulk formulations to Indian agrochemical companies as well as multinational corporations (MNCs). It began its journey by focusing on the import and registration of critical pesticide molecules (technical) that were not domestically produced in India. After product research, the company imported these molecules and registered them with the Central Insecticides Board and Registration Committee (CIBRC) under the Department of Agriculture, Government of India. Following successful registration, it marketed these molecules as technical and value-added end-use formulations to both domestic manufacturers and multinational corporations.
Since its inception in 2002, the company has expanded from selling technical products to companies to establishing its own manufacturing facility/plant for formulations in Dahej, Gujarat in December 2021. From this manufacturing facility, it produces and sells bulk formulations, branded products (own-brand products), and exports them to customers. Domestically, the company markets its branded products through a well-established dealer network in states such as Punjab, Haryana, Rajasthan, Uttar Pradesh, Gujarat, Maharashtra, Andhra Pradesh, and Telangana. Internationally, it exports products to countries such as the Dominican Republic, Turkey, Egypt, and the United Arab Emirates, ensuring complete adherence to all manufacturing and compliance standards.
Company Address
Mahamaya Lifesciences Ltd.
Unit No: DPT – 033, Ground Floor,
Plot No: 79 – 80, DLF Prime Tower,
Block, Okhla, Phase – 1
Delhi, New Delhi, 110020
Phone: +91-1146561474
Email: cs@mahamayalifesciences.com
Website: https://www.mahamayalifesciences.com/
IPO Registrar
Kfin Technologies Ltd.
Phone: 04067162222, 04079611000
Email: mahamaya.ipo@kfintech.com
Website: https://ipostatus.kfintech.com/